Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study

PLoS One. 2016 Nov 18;11(11):e0166745. doi: 10.1371/journal.pone.0166745. eCollection 2016.

Abstract

Background: Thoracic computed tomography (CT) scans are widely performed in clinical practice, often leading to detection of airway or parenchymal abnormalities in asymptomatic or minimally symptomatic individuals. However, clinical relevance of CT abnormalities is uncertain in the general population.

Methods: We evaluated data from 1361 participants aged ≥40 years from a Canadian prospective cohort comprising 408 healthy never-smokers, 502 healthy ever-smokers, and 451 individuals with spirometric evidence of chronic obstructive pulmonary disease (COPD) who had thoracic CT scans. CT images of subjects were visually scored for respiratory bronchiolitis(RB), emphysema(E), bronchial-wall thickening(BWT), expiratory air-trapping(AT), and bronchiectasis(B). Multivariable logistic regression models were used to assess associations of CT features with respiratory symptoms, dyspnea, health status as determined by COPD assessment test, and risk of clinically significant exacerbations during 12 months follow-up.

Results: About 11% of life-time never-smokers demonstrated emphysema on CT scans. Prevalence increased to 30% among smokers with normal lung function and 36%, 50%, and 57% among individuals with mild, moderate or severe/very severe COPD, respectively. Presence of emphysema on CT was associated with chronic cough (OR,2.11; 95%CI,1.4-3.18); chronic phlegm production (OR,1.87; 95% CI,1.27-2.76); wheeze (OR,1.61; 95% CI,1.05-2.48); dyspnoea (OR,2.90; 95% CI,1.41-5.98); CAT score≥10(OR,2.17; 95%CI,1.42-3.30) and risk of ≥2 exacerbations over 12 months (OR,2.17; 95% CI, 1.42-3.0).

Conclusions: Burden of thoracic CT abnormalities is high among Canadians ≥40 years of age, including never-smokers and smokers with normal lung function. Detection of emphysema on CT scans is associated with pulmonary symptoms and increased risk of exacerbations, independent of smoking or lung function.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Canada / epidemiology
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Outcome Assessment, Health Care
  • Population Surveillance
  • Prevalence
  • Pulmonary Disease, Chronic Obstructive / diagnostic imaging*
  • Pulmonary Disease, Chronic Obstructive / epidemiology
  • Pulmonary Disease, Chronic Obstructive / physiopathology*
  • Respiratory Function Tests
  • Self Report
  • Severity of Illness Index
  • Tomography, X-Ray Computed*

Grants and funding

The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); and industry partners Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, and Novartis. The project is led by researchers at RI-MUHC Montreal and the UBC Center for Heart Lung Innovation, Vancouver. Previous funding partners were CIHR (CIHR/ Rx&D Collaborative Research Program Operating Grants- 93326), the Respiratory Health Network of the FRSQ; and industry partners Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Other related funders include Forest, Amgen, Roche, CSL Behring, Grifolds, Genentech, Kamada, Merck, and Novartis Pharma Canada Inc. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.